Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
- Lecturer B
- Pharmaceutical & Biological Chemistry
- UCL School of Pharmacy
- Faculty of Life Sciences
Dr Min Yang has been a lecturer in the Department of Pharmaceutical & Biological Chemistry at the UCL School of Pharmacy since 2007. He undertook postdoctoral research with Prof. Benjamin G. Davis in the Chemistry Department, Oxford University from 2002 to 2006. He then moved to Cambridge to undertake postdoctoral research with Prof. Chris Abell on a microdroplet project in the Chemistry Department, Cambridge University from 2006 to 2007.
Dr Yang graduated from the Chemistry Department at Nanjing University in 1992 (BSc) and 1997 (MSc) under the supervision of Prof. Xiangzhen Sun and Prof. Yi Pan. He worked at the Nanjing Chemical Plant from 1992- 1994 and Procter & Gamble Technology (Beijing) Co. Ltd from 1997-1999. He carried out his PhD at the School of Applied Sciences, University of Huddersfield in Nov 1999 to under the supervision of Dr. Andrew. Laws and Prof. Mike I. Page.
He became a Member of Royal Society of Chemistry (MRSC) in 2003, member of American Chemistry Society (2010) and Fellow of the Higher Education Academy (2011). He is currently a visiting professor of Nanjing University and Xuzhou Medical College.
A focus of our research is the development proteomics and MS based methods to understand the role of novel targets and their inhibitors/targeted drugs for the pathology/therapy of diseases such as cancer. An example for the utility of this strategy is a provided by a comparative oncology study in which we were able to confirm a role for glycosyltransferases (GTs) in canine cancers using matched clinical samples and by application to the discovery of novel biomarkers of drug resistance in human ovarian cancer. The extended glyco-affinity proteomics strategy is also useful in understanding the cause of non-cancer conditions such as male infertility.
We also use a High Throughput Screening (HTS) MS methodology to understand their catalytic mechanism of plant GTs and their applications in the biosynthesis of novel anticancer drugs. Our anticancer drug discovery also focuses on targeting cancer related proteins (e.g. Heat Shock Protein 90) using carbohydrate modified clinical approved drug.